Back

Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection fraction in diabetic patients: a multicenter randomized-controlled trial

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: New treatment studies in heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Hajime Kihara

Kihara Cardiovascular Clinic, Asahikawa (Japan)

8 More presentations in this session

Presentation thumbnail
Sequential nephron blockade with diuretics improves diastolic dysfunction in patients with resistant hypertension, a substudy a the PHARES trial
Doctor D. Fouassier (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Inhaled iloprost, exercise hemodynamics, and ventricular performance in heart failure with preserved ejection fraction
Doctor J. Cheng (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Diuretic and renal effects of spironolactone and heart failure hospitalizations: A TOPCAT Americas analysis
Associate Professor A. Kalogeropoulos (Stony Brook, US)
Presentation thumbnail
Use of phenomapping to determine response of treatment by sacubitril/valsartan in patients with heart failure with reduced ejection fraction
Mr M. Godet (Rouen, FR)
Abstract Slides Video
Presentation thumbnail
Clinical predictors of NT-proBNP response to early initiation of sacubitril/valsartan after hospitalisation for decompensated heart failure: An analysis of the TRANSITION study
Doctor D. Pascual Figal (Murcia, ES)
Abstract Slides Video

Access the full session

Session thumbnail
New treatment studies in heart failure

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources